Small compounds inhibiting SHP2 and PROTACs are being developed, and 11 allosteric SHP2 inhibitors (such as PD-1, MEK, RTK, ERK, BRAF, and ALK) are undergoing clinical evaluation for cancer treatment. Here, ALK is linked to cancer.